Docencia
Incidence and Risk Factors for Invasive Pneumococcal Disease and Communityacquired Pneumonia in Human Immunodeficiency Virus–Infected Individuals in a High-income SeBng (01-04-2020)
Dra. Inés Suárez García.
Hospital Infanta Sofía, Madrid.
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial. (13-03-2020)
Dr. Pablo Bachiller Luque.
Unidad de Enfermedades Infecciosas. S. Medicina Interna Complejo Asistencial de Segovia
Comorbidity and polypharmacy among women living with HIV in British Columbia (28-02-2020)
Dr. Vicente Boix.
Unidad de Enfermedades Infecciosas. Hospital General Universitario de Alicante
Prevalence and incidence of HPV infection in men having sex with men enrolled in a PrEP study: A sub-study of the ANRS IPERGAY trial. (14-02-2020)
Dra. Ana González-Cordón.
Servicio de Enfermedades Infecciosas. Hospital Clínic de Barcelona.
Efficacy and safety of dolutegravirrilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, openlabel, phase 3 SWORD-1 and WORD-2 studies. (31-01-2020)
Dra. Hortensia Álvarez.
Unidad de Enfermedades Infecciosas, Servicio Medicina Interna. Complejo Hospitalario Universitario de Ferrol, A Coruña
One month of Rifapentine Plus Isoniazid to prevent HIV-related Tuberculosis (15-01-2020)
Dra. Inés Suárez-García.
Universidad Europea de Madrid. Hospital Universitario Infanta Sofía, Madrid.
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1 B, Double- Blind, Lacebocontrolled Trial (02-01-2020)
Dra. Isabel Viciana Ramos.
Servicio de Microbiología – UGC Infecciosos. Hospital Virgen de la Victoria, Málaga.
Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison (13-12-2019)
Dr. Pablo Bachiller Luque.
Enfermedades Infecciosas – S. Medicina Interna. Complejo Asistencial de Segovia.
Frailty Is an Independent Risk Factor for Mortality, Cardiovascular Disease, Bone Desease, and Diabetes Among Aging Adults With Human Immunodeficiency Virus (03-12-2019)
Dr. Vicente Boix.
Unidad de Enfermedades Infecciosas. Hospital General Universitario de Alicante. ISABIAL
Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV (15-11-2019)
Dra. Ana González-Cordón. Servicio de Enfermedades Infecciosas. Hospital Clínic de Barcelona.
Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States (05-11-2019)
Dra. Hortensia Álvarez. Unidad de Enfermedades Infecciosas, Servicio Medicina Interna. Complejo Hospitalario Universitario de Ferrol, A Coruña.
Effects of Pre-exposure Prophylaxis for the Prevention of Hiv Infection on Sexual Risk Behavior in Men Who Have Sex With Men: a Systematic Review and Meta-analysis (15-10-2019)
Dra. Inés Suárez-García. Hospital Infanta Sofía, Madrid.
Diverse Large HIV-1 Non-subtype B Clusters Are Spreading Among Men Who Have Sex With Men in Spain (01-10-2019)
Dra. Isabel Viciana. Unidad de Microbiología. Hospital Universitario Virgen de la Victoria, Málaga.
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial (17-06-2019)
Dr. Juan Luis Gómez Sirvent. Sección de infecciones. Hospital Universitario Virgen de las Nieves, Granada.
Switching from a protease inhibitor-based regimen to a dolutegravir-based regimen: a randomized clinical trial to determine the effect on peripheral blood and ileum biopsies from ART-suppressed HIV-infected individuals (03-06-2019)
Dra. Carmen Hidalgo. FEA de la UGC de Enfermedades Infecciosas. Hospital Universitario Virgen de las Nieves, Granada.
Immediate versus deferred switchin from a boosted protease inhibitor-based regimen to a Dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age? 50 years: final 96-week results of the NEAT022 study (14-05-2019)
Dra. María Saumoy. Unidad de VIH y ETS. Servicio de Enfermedades Infecciosas. Hospital Universitario Bellvitge, Barcelona
Contribución de los factores de riesgo tradicionales y relacionados con el VIH en el cáncer no definitorio de sida, el IAM, la enfermedad hepática terminal y la enfermedad renal terminal en pacientes infectados por el VIH en EEUU y Canadá: estudio colaborativo de cohortes. (30-04-2019)
Dr. Pablo Ryan. Servicio de Medicina Interna. Hospital Universitario Infanta Leonor, Madrid
Persistent low-level viremia while on antiretroviral therapy is an independent risk factor for virologic failure (15-04-2019)
Dr. Enrique Bernal. Unidad de Enfermedades Infecciosas. Hospital General Universitario Reina Sofía, Murcia.
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study (01-04-2019)
Dra. Luz Martín Carbonero. Medicina Interna. Hospital Universitario La Paz, Madrid.
